Full Press Release Details
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy.
PRAX
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Key Takeaway: Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Price reaction · baseline $310.38 (2026-04-02 close) · clean, no other PRAX news in the window
day 0 close
-0.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+61%
120-day peak, hindsight
Typical move
23.7%
average across 12 past catalysts
Cash runway
~53 mo
Minimal dilution risk
Lead asset
vormatrogine
Phase 3 · Epilepsy, Tonic-Clonic